Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset

Roche licenses Alector's Parkinson's disease therapy for up to $1.27 billion

Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, with $100 million upfront. The deal sent Alector's shares surging over 70% in premarket trading.